Appointments at Cardiocore and HUNT Biosciences – People on the move
Rick Turner has joined Cardiocore as a member of its scientific consulting team. In this capacity Turner will help clinical trial sponsors that are working with the cardiac testing services provider.
This entails Turner, who has written seven books and 100s of journal articles on cardiac safety research, assisting with strategic planning, protocol development, expert reporting and regulatory submissions.
Turner previously worked as principal clinical submissions scientist at GlaxoSmithKline (GSK), which gave him experience of the internal processes and regulatory submission challenges faced by clinical trial sponsors.
DFB Pharmaceuticals has promoted of Maxwell Lea, III, to vice president business development and corporate finance. Lea has worked at DFB, which provides outsourcing services to the pharma industry, since 2002.
In his new role Lea will manage DFB's capital raising and financing activities, business development initiatives and strategic planning. In addition he will also take charge of business development at Healthpoint, a DFB affiliate company.
HUNT Biosciences has appointed Per Foss as its new CEO. The company is the commercial arm of the HUNT Study and provides biomarker discovery and validation services to the pharma industry.
Amar Sethi has been appointed as vice president of science and technology at Pacific Biometrics (PBI), a provider of central laboratory services for clinical drug development.
In this capacity Sethi will participate in developing strategic plans and report directly to the company’s CEO. Sethi joins the company having spent a period as a postdoctoral fellow at the National Heart, Lung, and Blood Institute, Pulmonary and Vascular Medicine Branch, National Institutes of Health (NIH).
